Postdoctoral Fellow, Johns Hopkins
University School of Medicine, 2000
Postdoctoral Fellow, Rockefeller
University, 1999
Ph.D., University of Alberta, 1997
Pharm.D., University of Tehran, 1989
Research Interests
Our research is appropriately described
as "the application of synthetic organic chemistry to problems in
biology". Specific areas currently under investigation include:
Designing Protein Kinase Inhibitors Through Target-Based
Strategies Using Molecular Modeling, Synthetic and
Biochemical Tools.
Mechanistic Studies of Protein Tyrosine Kinase Activation
by
Metals.
Novel Strategies in the Solid-Phase
Synthesis.
Novel Approaches in Designing Bifunctional
Antiinfective agents.
Selected
Publications:
1.
Ye, G., Ayrapetov, M., Nam, N. H., Sun, G.,
Parang, K. Solid-phase binding assays of peptides using EGFP-Src SH2
domain fusion protein and biotinylated Src.
Bioorg. Med. Chem. Lett.
(2005)
in press.
2.
Parang K., Sun G. Recent advances in the
discovery of Src kinases
inhibitors. Expert
Opin. Ther. Patents
(2005)
in press.
3.
Ahmadibeni Y., Parang K. Polymer-bound
oxathiaphospholane: A solid-phase reagent for regioselective
monothiophosphorylation and monophosphorylation of unprotected
nucleosides and carbohydrates.
Org. Lett.
(2005)
7,
1955-1958.
4.
Ahmadibeni Y., Parang K. Solid-phase reagents
for selective monophosphorylation of carbohydrates and nucleosides.
J. Org. Chem.
(2005)
70,
1100-1103.
5.
Ayrapetov M. K., Nam N. H., Ye G. Kumar A.,
Parang K., Sun G. Functional
diversity of Csk, Chk, and Src SH2 domains due to a single residue
variation. J. Biol. Chem.
(2005)
280,
25780-25787.
6.
Carballeira N. M., O’Neill, R., Parang K.
Racemic and optically active 2-methoxy-4-oxatetradecanoic acids: Novel synthetic fatty acids with selective antifungal
properties. Chem.
Phys. Lipids
(2005)
136, 47-54.
7.
Lin, X., Ayrapetov, M. K., Lee, S., Parang, K.,
Sun, G. Probing the communication between the regulatory and catalytic
domains of a protein tyrosine kinase,
Csk.
Biochemistry
(2005)
44,
1561-156.
8.
Parang K., Sun G. Protein kinase inhibitors in
drug discovery. Drug
Discovery Handbook
(2005)
Wiley-Interscience, New Jersey, Ed. Gad, S. C. 1191-1257.
9.
Nam N. H., Ye G., Sun G., Parang K.
Conformationally Constrained
Tetrapeptide Analogues of pYEEI as Src-SH2 Domain Inhibitors.
J. Med. Chem. (2004)
47,
3131-3141.
10.
Nam N. H., Pitts R., Sun G., Sardari S., Tiemo
A., Xie M., Yan B., Parang K. Design of Tetrapeptide Ligands as
Inhibitors of the Src SH2 Domain.
Bioorg. Med. Chem. (2004)
12,
779-787.
11.
Lee S., LinX., Nam N. H., Parang K., Sun G.
Determination of the Substrate-Docking Site of Protein Tyrosine Kinase
Csk. Proc. Nat. Acad.
Sci.
(2003)
100,
14707-14712.
12.
Parang K., Polymer-supported reagents for methylphosphorylation and phosphorylation
of Carbohydrates.
Bioorganic Med. Chem. Lett.
(2002)
12, 1863-1866.
13.
Parang K., Till J. H., Ablooglu A. J., Kohanski
R. A., Hubbard S. R., Cole P. A., Mechanism-based design of a protein
kinase inhibitor. Nature
Structural Biology
(2001)
8,
37-41.
14.
Parang K., Fournier E. J.-L., Hindsgaul O., A
solid phase reagent for the capture phosphorylation of carbohydrate and
nucleosides.
Org. Lett.
(2001)
3,
307-309.
For more
information, contact:
College of Pharmacy
Fogarty Hall, 41 Lower College Road, Kingston, RI 02881
Phone: 401-874-5842, Fax: 401-874-2181
E-mail:
pharmcol@etal.uri.edu.
The
University is an affirmative action/equal opportunity employer.
All rights reserved
